Gene expression dynamics of immune mediators in chronic myeloid leukemia patients treated with imatinib

BESTACH, YESICA; BORDONE, JAVIER; PEREZ, MARIEL; LARRIPA, IRENE BEATRIZ; LINCANGO YUPANKI, MARCO; MARIANO, ROMINA; ARANGUREN, PEDRO NEGRI; BELLI, CAROLINA BÁRBARA; TOLOZA, MARIA JAZMIN; CAMACHO, MARÍA FERNANDA; TARQUI, MELISSA; ENRICO, ALICIA

virtual

Congreso; LXVI Reunion anual SAIC 2021; 2021

SAIC

Imatinib was the first inhibitor approved for chronic myeloid leukemia (CML). Besides its direct oncokinase inhibition, the induction of an immune antitumor mechanism has also been suggested.The aim was to describe the gene expression dynamics of IL2, CIITA, TBET, GATA3, RORGT, FOXP3 and EOMES in CML at diagnosis and during the first year of treatment.Total RNA from peripheral blood samples was collected from 79 CML patients (34 serially followed) at diagnosis (n:23) or under treatment at 3 (n:41), 6 (n42) or 12 (n:26) months classified according to the molecular response at each time. Gene expression was evaluated by quantitative real-time PCR applying the comparative method 2-ΔCT relative to GAPDH gene. Statistical analyses were performed using the InfoStat software v2019 and p-values